-
Roth Capital Analyst Squares Up Against Hedge Fund In Ligand Pharma
Wednesday, July 29, 2015 - 3:18pm | 522Read More...Correction: A previous version of this article stated Cantor Fitzgerald's Irina Rivkind Koffler had a Hold rating on Ligand, which was incorrect. The analyst discontinued her coverage of the company on July 10. CJS Securities and Craig-Hallum's ratings on Ligand have also been added to the article...
-
Cantor Analyst: Durect Is Worth $3/Share, So Buy It
Wednesday, June 24, 2015 - 1:53pm | 297Read More...In a report issued Tuesday, Cantor Fitzgerald analyst Irina Rivkind Koffler reiterated a Buy rating and $3.00 price target on shares of DURECT Corporation (NASDAQ: DRRX), a micro-cap specialty pharmaceutical company. The firm likes the company in account of its “attractive post-operative...
